Compare CYCU & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CYCU | PMVP |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.3M | 72.2M |
| IPO Year | 2021 | 2020 |
| Metric | CYCU | PMVP |
|---|---|---|
| Price | $2.39 | $1.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 128.9K | ★ 436.5K |
| Earning Date | 11-16-2026 | 11-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,771,485.00 | N/A |
| Revenue This Year | $13.37 | N/A |
| Revenue Next Year | $66.84 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.01 | $1.02 |
| 52 Week High | $15.52 | $1.91 |
| Indicator | CYCU | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 45.17 | 44.52 |
| Support Level | $0.03 | $1.24 |
| Resistance Level | $2.77 | $1.38 |
| Average True Range (ATR) | 0.26 | 0.11 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 49.35 | 47.06 |
Cycurion Inc. provides information technology security solutions through its subsidiaries. The company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company has one reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.